Non-Small Cell Lung Cancer Market

The Non-Small Cell Lung Cancer market is expected to increase with a CAGR of 10.7% during the study period of 2017-2030.
The total Non-Small Cell Lung Cancer incident cases were 484,726 in 7MM in 2017.

Increase use of biomarker testing, increase incidence of NSCLC, increase in the mutation specific trials activity & approval, and competitive landscape are some of the leading factors expected to drive the Non-Small Cell Lung Cancer market in the coming years.

The key players in Non-Small Cell Lung Cancer market include Novartis, Merck, KGaA, Eli Lilly and Company, Hoffmann-La Roche, Xcovery, BeyondSpring Pharmaceuticals, OSE Immunotherapeutics, Sanofi, Takeda, AbbVie and others.

For more detailed information visit: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-market